Results 151 to 160 of about 3,168 (197)

Assessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study. [PDF]

Bone Rep
Zanchetta MB, Gonzalez-Pernas M, Jerkovich F, Pingel J, Schwartz N, Erdociain L, Zanchetta JR.   +6 more
europepmc   +1 more source

Socioeconomic vulnerability and osteoporosis treatment disparities during COVID-19 lockdown among U.S. medicare enrollees who initiated romosozumab. [PDF]

Osteoporos Int
Liu Y, Arora T, Zhang J, Sen B, Becker D, Sun R, Yun H, Saag KG, Curtis JR.   +8 more
europepmc   +1 more source

Effects of romosozumab and teriparatide on hip bone using 3D-SHAPER in postmenopausal women with osteoporosis. [PDF]

JBMR Plus
Lewiecki EM, Betah D, Humbert L, Libanati C, Oates M, Shi Y, Winzenrieth R, Ferrari S, Omura F.   +8 more
europepmc   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis. [PDF]

Arthritis Rheumatol
Adami G, Pollastri F, Fassio A, Montanari F, Piccinelli A, Benini C, Pasetto E, Dartizio C, Gatti D, Rossini M, Viapiana O.   +10 more
europepmc   +1 more source

Real-World Osteoporosis Pharmacotherapy in the UAE: Prescribing Trends, Adherence, and Patient Beliefs. [PDF]

Healthcare (Basel)
Alnuaimi MAA, Rabbani SA, Alnaeimi KEA, Obaid KAA, Shah SS, El-Tanani M, Alam A.   +6 more
europepmc   +1 more source

Romosozumab for osteoporosis.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Romosozumab for the treatment of osteoporosis

Expert Opinion on Biological Therapy, 2017
Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway. Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD ...
Leonardo Bandeira, E Michael Lewiecki, John P Bilezikian   +2 more
exaly   +3 more sources

Romosozumab in the Treatment of Osteoporosis

Immunotherapy, 2020
Osteoporosis is a disease characterized by weakening of the bone architecture, which leads to an increased risk of fracture. There has been interest in the development of osteoanabolic agents that can increase bone mass and reverse the deteriorating architecture of osteoporotic bone.
Alexandra O Kobza, Alexandra Papaioannou, Arthur N Lau, Jonathan D Adachi   +3 more
openaire   +2 more sources

Romosozumab

Reactions Weekly
  +10 more sources

Utilization of Romosozumab in Primary Care

Journal of Pharmacy Technology, 2023
Objective: The objective of the study is to highlight the role and safety of romosozumab in patients at high risk of fractures in primary care. Data Sources: A systemic database search of PubMed/MEDLINE, ClinicalTrials.gov, and Cochrane Library was conducted for articles with keywords romosozumab, osteoporosis, and safety between inception and July ...
Soon Hye Yang, Neha Mittal, Amanda L. Bell, Christian E. Bell   +3 more
openaire   +2 more sources